Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma

Clinical trial NCT04068831 · COMPLETED

Trial details

NCT number: NCT04068831
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Renal Cell Carcinoma Fumarate Hydratase Deficient Renal Cell Carcinoma Succinate Dehydrogenase Deficient Renal Cell Carcinoma

Start date: 2019-08-22
Primary completion: 2023-12-06
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.